Antithrombin Resistance Rescues Clotting Defect of Homozygous Prothrombin-Y510N Dysprothrombinemia

Abstract

A patient with hematuria in our clinic was diagnosed with urolithiasis. Analysis of the patient's plasma clotting time indicated that both activated partial thromboplastin time (52.6 seconds) and prothrombin time (19.4 seconds) are prolonged and prothrombin activity is reduced to 12.4% of normal, though the patient exhibited no abnormal bleeding phenotype and a prothrombin antigen level of 87.9%. Genetic analysis revealed the patient is homozygous for prothrombin Y510N mutation. We expressed and characterized the prothrombin-Y510N variant in appropriate coagulation assays and found that the specificity constant for activation of the mutant zymogen by factor Xa is impaired approximately fivefold. Thrombin generation assay using patient's plasma and prothrombin-deficient plasma supplemented with either wild-type or prothrombin-Y510N revealed that both peak height and time to peak for the prothrombin mutant are decreased; however, the endogenous thrombin generation potential is increased. Further analysis indicated that the thrombin mutant exhibits resistance to antithrombin and is inhibited by the serpin with approximately 12-fold slower rate constant. Protein C activation by thrombin-Y510N was also decreased by approximately 10-fold; however, thrombomodulin overcame the catalytic defect. The Na⁺-concentration-dependence of the amidolytic activities revealed that the dissociation constant for the interaction of Na⁺ with the mutant has been elevated approximately 20-fold. These results suggest that Y510 (Y184a in chymotrypsin numbering) belongs to network of residues involved in binding Na⁺. A normal protein C activation by thrombin-Y510N suggests that thrombomodulin modulates the conformation of the Na⁺-binding loop of thrombin. The clotting defect of thrombin-Y510N appears to be compensated by its markedly lower reactivity with antithrombin, explaining patient's normal hemostatic phenotype.

Keywords

prothrombin - protein C - prothrombinase - thrombomodulin - antithrombin

Author Contributions

Y.L. designed experiments and performed research; B.O.V. performed molecular modeling; I.B. performed the cell permeability assay; Q.D. and X.W. supervised studies conducted in Ruijin Hospital with proband's plasma. A.R.R. analyzed data, wrote the paper, and supervised the project. All authors approved the final version of the manuscript.

Publication History

Received: 04 March 2021

Accepted: 12 July 2021

Accepted Manuscript online:
13 July 2021

Article published online:
05 September 2021

• References

• 1 MacGillivray RT, Degen SJ, Chandra T, Woo SL, Davie EW. Cloning and analysis of a cDNA coding for bovine prothrombin. Proc Natl Acad Sci U S A 1980; 77 (09) 5153-5157
• 2 Krishnaswamy S, Church WR, Nesheim ME, Mann KG. Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism. J Biol Chem 1987; 262 (07) 3291-3299
• 3 Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53 (04) 505-518
• 4 Esmon CT, Lollar P. Involvement of thrombin anion-binding exosites 1 and 2 in the activation of factor V and factor VIII. J Biol Chem 1996; 271 (23) 13882-13887
• 5 Esmon CT, Owen WG, Jackson CM. The conversion of prothrombin to thrombin. V. The activation of prothrombin by factor Xa in the presence of phospholipid. J Biol Chem 1974; 249 (24) 7798-7807
• 6 Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003; 23 (01) 17-25
• 7 Esmon CT. Molecular events that control the protein C anticoagulant pathway. Thromb Haemost 1993; 70 (01) 29-35
• 8 Dahlbäck B, Villoutreix BO. Molecular recognition in the protein C anticoagulant pathway. J Thromb Haemost 2003; 1 (07) 1525-1534
• 9 Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3 (08) 1800-1814
• 10 Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296 (5574): 1880-1882
• 11 Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109 (08) 3161-3172
• 12 Mosnier LO, Meijers JC, Bouma BN. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001; 85 (01) 5-11
• 13 Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271 (28) 16603-16608
• 14 Benezra M, Vlodavsky I, Ishai-Michaeli R, Neufeld G, Bar-Shavit R. Thrombin-induced release of active basic fibroblast growth factor-heparan sulfate complexes from subendothelial extracellular matrix. Blood 1993; 81 (12) 3324-3331
• 15 Walker FJ, Fay PJ. Regulation of blood coagulation by the protein C system. FASEB J 1992; 6 (08) 2561-2567
• 16 Olson ST, Richard B, Izaguirre G, Schedin-Weiss S, Gettins PG. Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors. Biochimie 2010; 92 (11) 1587-1596
• 17 Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood 2005; 106 (08) 2605-2612
• 18 Peyvandi F, Mannucci PM. Rare coagulation disorders. Thromb Haemost 1999; 82 (04) 1207-1214
• 19 Sun WY, Witte DP, Degen JL. et al. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci U S A 1998; 95 (13) 7597-7602
• 20 Lancellotti S, Basso M, De Cristofaro R. Congenital prothrombin deficiency: an update. Semin Thromb Hemost 2013; 39 (06) 596-606
• 21 Girolami A, Ferrari S, Cosi E, Girolami B, Lombardi AM. Congenital prothrombin defects: they are not only associated with bleeding but also with thrombosis: a new classification is needed. Hematology 2018; 23 (02) 105-110
• 22 Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J. The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 1989; 8 (11) 3467-3475
• 23 Chen L, Yang L, Rezaie AR. Proexosite-1 on prothrombin is a factor Va-dependent recognition site for the prothrombinase complex. J Biol Chem 2003; 278 (30) 27564-27569
• 24 Le Bonniec BF, Esmon CT. Glu-192—-Gln substitution in thrombin mimics the catalytic switch induced by thrombomodulin. Proc Natl Acad Sci U S A 1991; 88 (16) 7371-7375
• 25 Rezaie AR. Reactivities of the S2 and S3 subsite residues of thrombin with the native and heparin-induced conformers of antithrombin. Protein Sci 1998; 7 (02) 349-357
• 26 Yang L, Rezaie AR. Calcium-binding sites of the thrombin-thrombomodulin-protein C complex: possible implications for the effect of platelet factor 4 on the activation of vitamin K-dependent coagulation factors. Thromb Haemost 2007; 97 (06) 899-906
• 27 Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994; 269 (02) 816-819
• 28 Ding Q, Yang L, Dinarvand P, Wang X, Rezaie AR. Protein C Thr315Ala variant results in gain of function but manifests as type II deficiency in diagnostic assays. Blood 2015; 125 (15) 2428-2434
• 29 Qureshi SH, Yang L, Manithody C, Iakhiaev AV, Rezaie AR. Mutagenesis studies toward understanding allostery in thrombin. Biochemistry 2009; 48 (34) 8261-8270
• 30 Bae JS, Kim YU, Park MK, Rezaie AR. Concentration dependent dual effect of thrombin in endothelial cells via Par-1 and Pi3 Kinase. J Cell Physiol 2009; 219 (03) 744-751
• 31 Rozewicki J, Li S, Amada KM, Standley DM, Katoh K. MAFFT-DASH: integrated protein sequence and structural alignment. Nucleic Acids Res 2019; 47 (W1) W5-W10
• 32 Wheeler TJ, Clements J, Finn RD. Skylign: a tool for creating informative, interactive logos representing sequence alignments and profile hidden Markov models. BMC Bioinformatics 2014; 15: 7
• 33 Huntington JA, Esmon CT. The molecular basis of thrombin allostery revealed by a 1.8 A structure of the “slow” form. Structure 2003; 11 (04) 469-479
• 34 Burley SK, Bhikadiya C, Bi C. et al. RCSB Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences. Nucleic Acids Res 2021; 49 (D1) D437-D451
• 35 Robert X, Gouet P. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res. 2014 42(Web Server issue) W320-324
• 36 Pettersen EF, Goddard TD, Huang CC. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci 2021; 30 (01) 70-82
• 37 Laimer J, Hiebl-Flach J, Lengauer D, Lackner P. MAESTROweb: a web server for structure-based protein stability prediction. Bioinformatics 2016; 32 (09) 1414-1416
• 38 Savojardo C, Fariselli P, Martelli PL, Casadio R. INPS-MD: a web server to predict stability of protein variants from sequence and structure. Bioinformatics 2016; 32 (16) 2542-2544
• 39 Rodrigues CHM, Pires DEV, Ascher DB. DynaMut2: assessing changes in stability and flexibility upon single and multiple point missense mutations. Protein Sci 2021; 30 (01) 60-69
• 40 Ouyang Z, Li G, Zhu H. et al. Corrigendum: construction of a five-super-enhancer-associated-genes prognostic model for osteosarcoma patients. Front Cell Dev Biol 2021; 8: 631453
• 41 Kurcinski M, Oleniecki T, Ciemny MP, Kuriata A, Kolinski A, Kmiecik S. CABS-flex standalone: a simulation environment for fast modeling of protein flexibility. Bioinformatics 2019; 35 (04) 694-695
• 42 Kuriata A, Gierut AM, Oleniecki T. et al. CABS-flex 2.0: a web server for fast simulations of flexibility of protein structures. Nucleic Acids Res 2018; 46 (W1) W338-W343
• 43 Tripodi A. Thrombin generation assay and its application in the clinical laboratory. Clin Chem 2016; 62 (05) 699-707
• 44 Lu Y, Villoutreix BO, Biswas I, Ding Q, Wang X, Rezaie AR. Thr90Ser mutation in antithrombin is associated with recurrent thrombosis in a heterozygous carrier. Thromb Haemost 2020; 120 (07) 1045-1055
• 45 Di Cera E, Guinto ER, Vindigni A. et al. The Na+ binding site of thrombin. J Biol Chem 1995; 270 (38) 22089-22092
• 46 Adams TE, Li W, Huntington JA. Molecular basis of thrombomodulin activation of slow thrombin. J Thromb Haemost 2009; 7 (10) 1688-1695
• 47 Henriksen RA, Owen WG, Nesheim ME, Mann KG. Identification of a congenital dysthrombin, thrombin Quick. J Clin Invest 1980; 66 (05) 934-940
• 48 O'Marcaigh AS, Nichols WL, Hassinger NL. et al. Genetic analysis and functional characterization of prothrombins Corpus Christi (Arg382-Cys), Dhahran (Arg271-His), and hypoprothrombinemia. Blood 1996; 88 (07) 2611-2618
• 49 Ding Q, Yang L, Zhao X, Wu W, Wang X, Rezaie AR. Paradoxical bleeding and thrombotic episodes of dysprothrombinaemia due to a homozygous Arg382His mutation. Thromb Haemost 2017; 117 (03) 479-490
• 50 Akhavan S, De Cristofaro R, Peyvandi F, Lavoretano S, Landolfi R, Mannucci PM. Molecular and functional characterization of a natural homozygous Arg67His mutation in the prothrombin gene of a patient with a severe procoagulant defect contrasting with a mild hemorrhagic phenotype. Blood 2002; 100 (04) 1347-1353
• 51 Miyawaki Y, Suzuki A, Fujita J. et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med 2012; 366 (25) 2390-2396
• 52 Djordjevic V, Kovac M, Miljic P. et al. A novel prothrombin mutation in two families with prominent thrombophilia–the first cases of antithrombin resistance in a Caucasian population. J Thromb Haemost 2013; 11 (10) 1936-1939
• 53 Sivasundar S, Oommen AT, Prakash O. et al. Molecular defect of ‘Prothrombin Amrita’: substitution of arginine by glutamine (Arg553 to Gln) near the Na(+) binding loop of prothrombin. Blood Cells Mol Dis 2013; 50 (03) 182-183
• 54 Bulato C, Radu CM, Campello E. et al. New prothrombin mutation (Arg596Trp, Prothrombin Padua 2) associated with venous thromboembolism. Arterioscler Thromb Vasc Biol 2016; 36 (05) 1022-1029
• 55 Mathews II, Padmanabhan KP, Ganesh V. et al. Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes. Biochemistry 1994; 33 (11) 3266-3279
• 56 Takagi Y, Kato I, Ando Y. et al. Antithrombin-resistant prothrombin Yukuhashi mutation also causes thrombomodulin resistance in fibrinogen clotting but not in protein C activation. Thromb Res 2014; 134 (04) 914-917
• 57 Bateman A, Martin MJ, Orchard S. et al; UniProt Consortium. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res 2021; 49 (D1): D480-D489